Home / Business and Economy / Twist Bioscience Soars on Barclays Upgrade
Twist Bioscience Soars on Barclays Upgrade
1 Jan
Summary
- Barclays increased TWST price target to $39 from $37.
- Fiscal 2026 revenue expected between $425M-$435M.
- Company targets adjusted EBITDA breakeven in Q4 2026.
Barclays has reiterated its Overweight rating on Twist Bioscience Corporation (NASDAQ:TWST), raising its price objective from $37 to $39. This adjustment is part of a broader 2026 industry outlook, with analysts noting a rebound in end markets and an under-owned healthcare sector poised for growth. The life sciences and diagnostics instruments industry is expected to surpass expectations in the upcoming year.
Twist Bioscience has unveiled its fiscal 2026 guidance, forecasting total revenue between $425 million and $435 million, an estimated increase of 13% to 15.5%. The DNA Synthesis and Protein Solutions Group anticipates a revenue of $194 million to $199 million, while the NGS Applications Group projects $231 million to $236 million. The company also expects its gross margin to exceed 52% for fiscal year 2026.
Looking ahead, Twist Bioscience Corporation has set a strategic goal to achieve adjusted EBITDA breakeven by the fourth quarter of fiscal 2026. This financial target underscores the company's focus on profitability and sustainable growth within the synthetic biology sector, building on its disruptive DNA synthesis platform.
